Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) TRx0237 in Subjects With Mild Alzheimer's Disease

Next Previous
X
Search
Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) TRx0237 in Subjects With Mild Alzheimer's Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydromethylthionine mesylate (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors TauRx Therapeutics

    • Most Recent Events

    • 26 Nov 2019 Results of pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine, using blood concentration data from 1,162 of 1,686 patients who had participated in either of two previously completed Phase 3 trials (TRx-237-015 and TRx-237-005) presented in a TauRx Therapeutics media release.
    • 26 Nov 2019 According to a TauRx Therapeutics media release, results from 1,162 patients who had participated in either of two previously completed Phase 3 trials that assessed the pharmacological activity were published in Journal of Alzheimers Disease.
    • 26 Nov 2019 Results of pharmacokinetic analyses (n=1162) published in the Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top